Treatment-resistant major depressive disorder remains inadequately treated with currently available antidepressants. Opioid receptors (ORs) are involved in the pathophysiology of depression yet remain an untapped therapeutic intervention. The m-d OR heteromer represents a unique signaling complex with distinct properties compared with m-and d-OR homomers; however, its role in depression has not been characterized. As there are no ligands exclusively targeting the m-d heteromer, we devised a strategy to selectively antagonize the function of the m-dOR complex using a specific interfering peptide derived from the dOR distal carboxyl tail, a sequence implicated in m-dOR heteromerization. In vitro studies using a minigene expressing this peptide demonstrated a loss of the unique pharmacological and trafficking properties of d-agonists at the m-d heteromer, with no effect on m-or d-OR homomers, and a dissociation of the m-dOR complex. Intra-accumbens administration of the TAT-conjugated interfering peptide abolished the antidepressant-like and anxiolytic-like actions of the d-agonist UFP-512 (H-Dmt-Tic-NH-CH(CH 2 -COOH)-Bid) measured in the forced swim test, novelty-induced hypophagia and elevated plus maze paradigms in rats. UFP-512's antidepressant-like and anxiolytic-like actions were abolished by pretreatment with either mOR or dOR antagonists. Overall, these findings demonstrate that the m-d heteromer may be a potential suitable therapeutic target for treatment-resistant depression and anxiety disorders.
INTRODUCTION
Treatment-resistant major depression remains a significant health, social and economic burden that is inadequately treated with currently available antidepressant medications that modulate serotonergic and noradrenergic neurotransmission. 1 Thus, pharmacological agents with alternative mechanisms of action are critically needed and necessary to address this unmet therapeutic need. Opioid receptors (ORs) and their endogenous ligands are involved in the pathophysiology of major depression, yet remain an untapped potential therapeutic intervention. [2] [3] [4] However, although m-opioid agonists such as morphine have been used in the clinic to successfully manage refractory depression, their clinical utility is limited by the development of tolerance and adverse side effects ensuing from mOR activation. [5] [6] [7] [8] [9] [10] [11] m-and d-ORs have been shown to form a heteromeric receptor complex possessing unique pharmacological and signalling properties. [12] [13] [14] [15] The m-d heteromer displays less of the functional desensitization and downregulation that limit the therapeutic utility of drugs targeting the mOR, 12, 14 rendering the m-d receptor complex a promising therapeutic target.
Although the pharmacological and molecular profile of the m-d heteromer in vitro is being elucidated, its physiological role in vivo is largely unknown. Exploring the m-d heteromer as a therapeutic target for treatment-resistant major depression is supported by behavioral, genetic and biochemical findings. First, d-opioid agonists, which we and others have shown to bind to and activate the m-d heteromer and regulate its intracellular trafficking, 12, 16 have potent antidepressant-like and anxiolytic-like effects in animal models. [17] [18] [19] [20] [21] [22] [23] [24] [25] Further, the analgesic effects of d-agonists are attenuated or abolished in mOR-gene-deleted animals and following pretreatment with mOR antagonists, 26, 27 supporting the notion that these ligands may in fact recruit the m-d OR heteromer for certain actions. Second, animals in which the genes for the mOR, dOR or Ga z (the inhibitory G-protein to which the m-d heteromer couples selectively) are deleted display depressive-like and anxiogenic behavior. 28 Finally, recent studies localize the m-d heteromer to brain nuclei implicated in mood and emotional processing, including the nucleus accumbens (NAc), 29 a subcortical brain region whose activity is reduced in patients with major depressive disorders. 30, 31 Furthermore, direct activation of the NAc with deep brain stimulation has shown promise in ameliorating depression and anxiety in patients. 32, 33 Thus, overall, several lines of evidence support exploring the activation of the m-d heteromer in the NAc in models of depression and anxiety.
In this study, we investigated the function of the m-d heteromer and its role in regulating depressive-like and anxiogenic behavior by determining its involvement in the mood-elevating properties of d-agonists. In the absence of selective ligands exclusively targeting the m-d heteromer, we devised a novel strategy to selectively antagonize the function of the m-d receptor complex through physical disruption. To this end, we designed a specific interfering peptide aimed at the distal carboxyl tail domain of the dOR, which has been implicated as a site of interaction between m-and d-ORs. After validating the use of the peptide to dissociate the m-d heteromer in vitro, we administered it in vivo into the NAc as a TAT-conjugate in order to interrogate the role of the m-d heteromer in the antidepressant-like and anxiolytic-like effects of UFP-512 (H-Dmt-Tic-NH-CH(CH 2 -COOH)-Bid), a d-agonist with high subnanomolar affinity at the m-d heteromer. 12 Overall, our findings indicate that activation of the m-d heteromer in the NAc by UFP-512 produced antidepressant-like and anxiolytic-like actions, which were completely abolished by dissociating the m-d heteromer or antagonizing either one of its component receptors. when both receptors were co-expressed) were generated as described previously.
MATERIALS AND METHODS

12
Minigene constructs
Complementary DNA fragments expressing either the distal 16 or 22 amino acids of the dOR carboxyl tail were subcloned into pcDNA3.1. The Transformer site-directed mutagenesis kit (Clontech, Mountain View, CA, USA) was used to insert the hemaglutinin epitope (YPYDVPDYA) at the NH 2 -terminal of the dOR carboxyl tail fragment using the same approach previously described. 13, 14 Cells were transfected using LipofectAMINE (Invitrogen, Burlington, ON, Canada) according to the manufacturer's protocols.
Cell membrane preparation
Membrane fractions (crude P2 fraction) and cell lysates were prepared from cells as described previously. 12, 14 Competition radioligand binding Experiments were performed in duplicate on cell membrane preparations with increasing concentrations of competing ligand (10 À 12 -10 À 4 M) as described in detail previously. 12 
Dot blotting analysis
Cell lysate supernatant was spotted onto nitrocellulose membrane and then incubated with anti-hemaglutinin antibody diluted 1:2000 (AB 3254, Chemicon, Temecula, CA, USA). Immunoreactivity was revealed by incubating with HRP-conjugated anti-chicken secondary antibody diluted 1:1000 (Bio-Rad, Hercules, CA, USA) followed by enhanced chemiluminescent reagents (KPL, Gaithersburg, MD, USA), and then exposing to film.
Immunoprecipitation studies
Membrane fractions were solubilized, incubated with anti-cMyc antibody (Millipore, Billerica, MA, USA) and then protein-G-agarose beads, followed by washing and solubilization in SDS sample for gel electrophoresis as described previously. 14 
SDS-polyacrylamide gel electrophoresis and immunoblotting
Membrane proteins were resolved on a 10% Tris-Glycine precast gel (Novex, San Diego, CA, USA) and subjected to denaturing SDSpolyacrylamide gel electrophoresis as described previously.
14 Membranes were incubated in FLAG antibody diluted 1: 5000 (Sigma, Saint Louis, MO, USA) or cMyc antibody diluted 1:1000 (Millipore). 
Stereotaxic surgery
Rats were mounted on a stereotaxic frame under isoflurane anesthesia. Stainless steel guide cannulae were implanted bilaterally into the NAc (AP þ 1.6, ML þ 3.0, DV À 6.9) at a 101 angle from the midline or into the lateral cerebral ventricle (AP À 0.8, ML þ 1.4, DV À 3.6) at 901 angle to the skull using co-ordinates from. 35 Guide cannulae were positioned 1 mm anterior to the NAc to prevent tissue damage at the target site. Cannulae were secured onto the skull using stainless steel screws and dental cement with the insertion of dummy stylets to maintain patency. Rats were allowed to recover, and behavioral testing was conducted 7 days following surgery. Placement of guide cannulae was verified by brain sectioning and histological examination at the end of the experiment.
TAT fusion peptides
A peptide derived from the distal portion of the dOR carboxyl tail (5 0 -VTACTPSDGPGGGAAA-3 0 ) identified as a m-d heteromerization interaction interface was conjugated to the HIV protein transduction domain TAT (5 0 -YGRKKRRQRRR-3 0 ) to create a TAT fusion peptide for transduction into neurons. 36 A scrambled sequence of the same 16 amino acids was used as control. Dansyl chloride was conjugated to the TAT peptide to allow for easy detection of the fusion peptide in vivo. Interfering or scrambled fusion peptides (15 pmol per side) were injected bilaterally into the NAc at concentrations previously reported in the literature. [37] [38] [39] Forced swim test This test was adapted from Porsolt et al. 40 Rats were placed in a cylindrical container filled to a depth of 30 cm with water (at 25 þ 1 1C). During the initial session, rats were allowed to swim without behavioral scoring for 15 min in order to induce immobility on test day. On the next day, animals were tested and their predominant behavior was recorded at 5-s intervals for 5 min using the time sampling method validated by Lucki et al. 41 Rats which floated in the water making only the necessary movements to maintain their head above water were deemed immobile. Following swim sessions, the rats were dried and placed under a heat lamp and monitored until recovery.
Dose-response curves of UFP-512's behavioral effects following intraNAc and intracerebroventricular (i.c.v.) administration were generated. In all subsequent experiments, the 1.5 mg and 80 nmol doses of UFP-512 were microinjected into the NAc and i.c.v., respectively. Naltrindole and CTOP were administered at 1 mg intraNAc and 10 nmol i.c.v. Agonist and antagonist doses used were derived from literature examining the effects of microinjection of opioid ligands into the NAc or i.c.v., and behavioral testing was conducted 30 min following the last injection. 17, 23, [42] [43] [44] [45] [46] [47] [48] [49] Elevated plus maze test 
Novelty-induced hypophagia test
Novelty-induced hypophagia was assessed in singly-housed rats. Animals were trained to drink a sweetened milk solution in their home cage for 3 days. Only animals that consumed milk solution were included. On the fourth day, the latency to drink milk solution and the amount consumed were assessed in the home cage. On the fifth and final day, rats were placed in a novel cage without corn cob bedding under bright light conditions and the latency to drink milk solution and amount consumed were assessed in this novel and anxiogenic environment.
Data analysis
Statistical analyses and graph generation were performed using GraphPad Prism software 3.01 (San Diego, CA, USA). The results were presented as means±s.e.m. Data from competition radioligand binding experiments were analyzed by nonlinear least-squares regression. An F-test was used to compare the coefficients of goodness-of-fit and to determine whether a two-site (biphasic competition curve with high-and low-affinity sites) or a one-site (monophasic competition curve with one high-or low-affinity site) analysis was a statistically significant better fit for the radioligand competition binding curves.
One-way analysis of variance followed by Dunnett's post hoc analysis was used to assess statistical significance of cell surface radioligand binding, forced swim test, elevated plus maze, novelty-induced hypoghagia and locomotor activity data. Po0.05 was deemed significant. Table S1 ), a phenomenon which occurs only when the mOR is complexed with dOR.
RESULTS
Effect of the interfering dOR
12 Coexpression of the dOR carboxyl tail peptide minigene abolished UFP-512-induced displacement of high-affinity m-agonist binding to the m-dOR heteromer (Figure 1a) , and resulted in a right-ward shift to a monophasic low-affinity competition curve identical to UFP-512's binding to the mOR expressed alone (that is, mOR homomer) (Figure 1b ; Supplementary Table S1 ). The minigene expressing the control peptide had no effect (Figure 1c ; Supplementary  Table S1 ). Similar set of effects was observed with SNC80, another class of d-agonist (Supplementary Figures S1A-C) . Furthermore, the interfering peptide had no effect on UFP-512 (Figure 1d Figure  S1D) . Thus, the interfering peptide disrupted the m-d heteromer as it abolished d-agonist-induced internalization of mOR-an effect seen only when the two receptors are complexed in a heteromer.
Effect of the interfering dOR carboxyl tail peptide on the coimmunoprecipitation of m-and d-Ors Dot blotting analysis confirmed the expression of the peptides encoded by the minigenes in transfected cells (Figure 2b) . Immunoprecipitation of mOR using a cMyc antibody and subsequent blotting using a FLAG antibody targeting the dOR revealed an immunoreactive band atB65-70 kDa consistent with immunoprecipitation of the dOR (Figure 2c, lane 1) . Expression of the interfering peptide resulted in a loss of the immunoreactive band atB65-70 kDa and prevented coimmunoprecipitation of the dOR with the mOR, suggesting the dissociation of m-and d-ORs in the m-d heteromer (Figure 2c, lane 2) . The control peptide had no effect on m-and d-OR coimmunoprecipitation (Figure 2c,  lane 3) . The expression of both receptors and specificity of both antibodies were confirmed (Figure 2c, lanes 4-10) .
Effect of intra-accumbens microinjection of the TAT-conjugated dOR carboxyl tail interfering peptide on d-agonist-induced antidepressant-like action in the forced swim test In order to determine the contribution of the m-dOR heteromer in NAc to the antidepressant-like action of the d-agonist UFP-512, rats were microinjected with interfering peptide or a scrambled control peptide before UFP-512 and examined in the forced swim test model of behavioral despair. 40 In our study, we elected to use UFP-512 as it is devoid of convulsive activity, 23 has antidepressantlike and anxiolytic-like properties in animals, 23 does not affect locomtor activity, 23 recruits the mOR for its actions 12 and activates the m-d heteromer with the highest affinity in vitro.
12 Cannula placement in the NAc is illustrated (Supplementary Figure S2) . A dose-response curve of UFP-512's effects following intraNAc administration is shown (Supplementary Figure S3) . UFP-512 was administered at 1.5 mg intraNAc in all subsequent experiments. Microinjection of UFP-512 bilaterally into the NAc resulted in a significant reduction in the duration of immobility in the forced swim test, suggestive of antidepressant-like action (Figure 3a) . Pretreatment with TAT-conjugated interfering peptide reversed the UFP-512-induced reduction in immobility, whereas the scrambled peptide control had no effect (Figure 3a) . The tricyclic antidepressant imipramine administered intraperitoneally served as a positive control showing a significant reduction in immobility (Figure 3b ). Dissociating the m-dOR heteromer in NAc had no effect on imipramine's antidepressant effects in the forced swim test (Figure 3b) . Fluoxetine has been shown to have negligible effect when administered alone in the forced swim test [50] [51] [52] and was thus used as a negative control. Thus, the dOR carboxyl tail interfering peptide selectively antagonized the antidepressant-like effects of agonists acting at the m-dOR heteromer and this receptor complex mediated the antidepressant-like effects of d-agonist UFP-512 in the NAc. Effect of intra-accumbens microinjection of the TAT-conjugated dOR carboxyl tail interfering peptide on d-agonist-induced anxiolytic-like and antidepressant-like action in the noveltyinduced hypophagia test In order to determine the contribution of m-dOR heteromers in the NAc to the anxiolytic-like and antidepressant-like effects of UFP-512 in a model of anxiety and depression featuring anhedonia, 53 a significant clinical issue in patients with mood disorders, rats were microinjected bilaterally into the NAc with interfering peptide before UFP-512 and examined in the novelty-induced hypophagia test. Intra-accumbens injection of UFP-512 resulted in a significant reduction in the latency to drink milk in a novel environment (Figure 4a ). Pretreatment with TAT-conjugated interfering peptide followed by UFP-512 reversed the UFP-512-induced reduction in latency to drink milk, whereas the scrambled peptide control had no effect (Figure 4a ). The benzodiazepine diazepam resulted in a significant reduction in latency to drink milk and served as a positive control (Figure 4b) .
To investigate the contribution of dOR and mOR to UFP-512's antidepressant-like and anxiolytic-like action in the noveltyinduced hypophagia paradigm, rats received i.c.v. microinjections of the d-antagonist naltrindole or the m-antagonist CTOP before UFP-512 administration. A dose-response curve of UFP-512's effects following i.c.v. administration is shown (Supplementary Figure S4) . UFP-512 was administered at 80 nmol i.c.v. in all subsequent experiments. i.c.v. pretreatment with either naltrindole or CTOP followed by UFP-512 reversed the UFP-512-induced decrease in latency to drink milk (Figure 4c) . Thus, both m-and d-ORs are required for the anxiolytic-like and antidepressant-like action of UFP-512 in this behavioral paradigm.
Effect of intra-accumbens microinjection of the TAT-conjugated dOR carboxyl tail interfering peptide on d-agonist-induced anxiolytic-like action in the elevated plus maze In order to determine the contribution of the m-dOR heteromer in NAc to the anxiolytic-like effects of UFP-512, rats were respectively. An F-test was used to compare the coefficients of the goodness-of-fit and to determine whether a two-site (biphasic competition curve with high-and low-affinity sites) or a one-site (monophasic competition curve with one high-or low-affinity site) analysis was a statistically significant better fit for the radioligand competition binding curves. Results shown are mean ± s.e.m. and curves are representative of n ¼ 3-6 experiments performed in duplicate.
m-d heteromer mediates antidepressant-like action N Kabli et al microinjected with interfering peptide before UFP-512 and examined in the elevated plus maze, a model of anxiety with great face and construct validity. 54 Intra-accumbens injection of UFP-512 resulted in a significant increase in the time spent in the open arms of the elevated plus maze, which is suggestive of anxiolytic-like action (Figure 5a ). Pretreatment with TAT-conjugated interfering peptide reversed the UFP-512-induced increase in time spent in open arms, whereas the scrambled peptide control had no effect (Figure 5a ). The benzodiazepine diazepam served as a positive control (Figure 5b ). Both naltrindole and CTOP reversed the increased time spent in open arms of the maze induced by UFP-512, but had no effect on their own (Figure 5c ). Thus, both m-and d-ORs are also required for the anxiolytic-like action of UFP-512.
In separate experiments, UFP-512 did not alter nociceptive thresholds in the tail immersion assay at any dose or time point tested (Supplementary Figure S5) . Thus, at the doses used, UFP-512 selectively produced antidepressant-like and anxiolytic-like effects-but not analgesia-through the NAc. Further, neither UFP-512 nor interfering or scrambled peptides altered locomotor activity counts (Supplementary Figure S6A) or patterns (Supplementary Figure S6B) . Thus the behavioral effects of the TAT peptides and the UFP-512-induced reduction in immobility, increased time spent in open arms and reduced latency to drink milk in the forced swim test, elevated plus maze and noveltyinduced hypophagia paradigms, respectively, were not due to non-specific effects on locomotion.
DISCUSSION
Our findings indicate that activation of the m-d heteromer in the NAc produced potent antidepressant-like and anxiolytic-like effects similar in magnitude to the effects of clinically-relevant antidepressants and anxiolytics in rodent models. Dissociating the m-d heteromer with an interfering peptide which had no effect on m or d homomeric ORs or antagonizing either one of the component receptors of the heteromer in NAc abolished d-agonistinduced antidepressant-like and anxiolytic-like effects in animal models of behavioral despair, anhedonia and anxiety.
The antidepressant-like and anxiolytic-like effects of m-d heteromer activation in the NAc may be accounted for by modulation of dopamine release, as supported by anatomical, biochemical, pharmacological and behavioral lines of evidence. In the NAc, m-and d-ORs are co-expressed on nerve terminals of GABAergic interneurons which synapse onto local and projection dopaminergic neurons. [55] [56] [57] [58] [59] Activation of the m-d heteromer would inhibit GABA (gamma-aminobutyric acid) release and thus disinhibit dopaminergic neurons resulting in dopamine release, as supported by anatomical data. 56 Indeed, dopamine release in the NAc occurs within minutes following infusion of d-agonists into the same region, 60, 61 coincides with the peak behavioral effects we observed in our study and likely accounts for the rapid reversal of depressive-like and anxiogenic behavior in our animals. 62 In confirmation of this hypothesis, d-agonists-induce dopamine release in the NAc in a manner that is reversed by either dOR or 4 and 8, respectively ) or in the presence of expressed interfering (c) lanes 5 and 9, respectively) or control peptide (c) lanes 6 and 10, respectively). The specificity of the cMyc and FLAG antibodies, respectively, is demonstrated by the absence of an immunoreactive signal in membranes from cells expressing FLAG-tagged dOR and cMyc-tagged mOR, respectively (c) lanes 7 and 11, respectively). Blots have been cropped to enhance clarity and conciseness.
m-d heteromer mediates antidepressant-like action N Kabli et al mOR antagonists, 61 suggesting involvement of the m-d heteromer. Furthermore, enhanced dopamine release represents the mechanism of action of buproprion in the NAc and accounts for the rapid onset of action of this and other antidepressant agents. 62, 63 Further, activation of the m-d heteromer modified features of despair, anhedonia and anxiety, suggestive of a common mechanism, likely increased phasic dopamine release, in alleviating depressive-like and anxiogenic behavior at the level of the NAc.
Our data solidify the case for opioidergic interventions improving depressive and anxiety-related symptoms through the NAc. Opioids, by modulating the excitability of the NAc and inducing dopamine release, may restore dopaminergic tone in the NAc of depressed patients. Whereas the utility of m-agonists in reversing depressive and anxiogenic behavior in animal models and humans is limited, d-agonists produce potent and welldocumented antidepressant-like and anxiolytic-like effects, presumably through the activation of the m-d receptor complex. In contrast with mOR and dOR which desensitize, the m-d OR heteromer remains functional following prolonged exposure to opioids, 12, 14 Depressive-like behavior was assessed using the forced swim test following the last injection. Rat behavior was scored, whereby the predominant behavior for each interval was recorded according to the Lucki method. 41 Immobility represented no activity except that which is required to keep the rat's head above water. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Dunnett post hoc analysis (***Po0.001 relative to saline-treated rats; n ¼ 6-12 animals per group). Thr-Pen-Thr-NH2) followed by UFP-512 or saline. Anhedonia was assessed following the last injection. The latency to drink from palatable milk solution in a novel and stressful environment (a measure of anhedonia) was used as an index of anxiolytic-like antidepressant-like action. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Dunnett post hoc analysis (*Po0.05, **Po0.01, ***Po0.001 relative to saline-treated rats; n ¼ 4-9 animals per group). Our findings also highlight the NAc as an important neural modulator of depressive-like and anxiogenic behavior that must not be overlooked for its roles beyond addiction and motivation. Traditionally, the frontal cortex and hippocampus as well as the amygdala have garnered the most attention in studies of depression and anxiety, respectively. 66, 67 However, these three brain regions all send glutamatergic projections to modulate the function of the NAc. 66 Thus, emotional processing through the NAc would be shaped by cognitive, contextual and emotional memory-dependent inputs. Further, a critical component of depression is anhedonia, or a blunted ability to experience pleasurable or rewarding stimuli, which implicates the mesolimbic reward circuitry in the pathophysiology of depression. Indeed, a number of neuroimaging studies have demonstrated perturbations in the mesolimbic reward system. For example, women with major depressive disorder display reduced NAc activity in response to positive stimuli. 30 Further, deep brain stimulation of the NAc has been has shown promise in reversing depressive symptoms such as anhedonia in patients with major depression and anxiety. 32, 33 The NAc is also implicated in modulating depressive behavior in rodent models. 63, [67] [68] [69] [70] Thus, modulating neurotransmission in the NAc may prove to be a fruitful strategy in individuals with major depression.
In conclusion, our data provide evidence of the role of the m-d opioid receptor heteromer in mediating antidepressant-like and anxiolytic-like behaviors in animal models. Future efforts should be aimed at designing selective m-d heteromer ligands and mapping the role of the m-d heteromer in various brain loci in order to allow for further exploration of this attractive therapeutic target for the management of treatment-resistant major depression. Available treatment strategies focusing on serotonergic and monoaminergic neurotransmitter mechanisms only work for a proportion of patients and only begin to exert their effects weeks following their administration. Thus, faster-acting therapeutic agents with alternate mechanisms of action are needed. Coupling to a distinct signal-transduction pathway and resisting the desensitization that is characteristic of mORs render the m-d heteromer a therapeutic target worthy of further investigation. Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Dunnett post hoc analysis (*Po0.05, **Po0.01, ***Po0.001 relative to saline-treated rats; n ¼ 4-9 animals per group).
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